Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).
Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, Knorr B, Lawrence D, Ossa D, Wang W, Maspero JF. Castro M, et al. Among authors: kerwin e. EClinicalMedicine. 2021 Apr 25;35:100847. doi: 10.1016/j.eclinm.2021.100847. eCollection 2021 May. EClinicalMedicine. 2021. PMID: 33997741 Free PMC article.
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.
Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. Wenzel SE, et al. Among authors: kerwin e. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8. Am J Respir Crit Care Med. 2009. PMID: 19136369 Clinical Trial.
Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H. Tashkin DP, et al. Among authors: kerwin e. Int J Chron Obstruct Pulmon Dis. 2012;7:43-55. doi: 10.2147/COPD.S27319. Epub 2012 Feb 3. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22334768 Free PMC article. Clinical Trial.
Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H. Doherty DE, et al. Among authors: kerwin e. Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22334769 Free PMC article. Clinical Trial.
Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H. Tashkin DP, et al. Among authors: kerwin e. Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22334770 Free PMC article. Clinical Trial.
149 results